FDA pulls emergency use authorization of hydroxychloroquine for COVID-19

By AHJ Staff June 17, 2020

The U.S. Food and Drug Administration recently rescinded its emergency use authorization for hydroxychloroquine to treat COVID-19. Based on new evidence, the agency said that the potential benefits of taking hydroxychloroquine and chloroquine to treat COVID-19 did not outweigh the risks (The New York Times).

AHJ Staff

American Healthcare Journal is healthcare’s No. 1 source for the latest insights, news and analysis. An authoritative, digital-first and editorially independent publication committed to providing decision makers with unparalleled thought leadership and objective, industry-focused information to help them run their businesses in the new era of healthcare.

Newsletter
Enter your email address to
subscribe to our newsletter.

Thank you for Signing Up
Please correct the marked field(s) below.
1,true,6,Subscriber Email,2
1,false,1,First Name,2
COVID-19 News
Featured Articles

September 11, 2020
Let’s Use the State of SNF Therapy Today as a Springboard for More Positive Outcomes

There’s no question that therapy today in skilled nursing facilities looks vastly different than it did several months ago — and for many years before that. What is yet to be determined is whether these changes can result in positive outcomes for all parties involved: patients, therapists and skilled nursing facilities.

Read More

September 9, 2020
Q&A: ACA Architect Predicts The Future Of Healthcare

Dr. Jonathan Gruber is the Ford Professor of Economics at the Massachusetts Institute of Technology and the Director of the Healthcare Program at the National Bureau of Economic Research. Highly involved in healthcare public policy, he was a key architect of Massachusetts’ health reform efforts, “Romneycare” from 2003 to 2006. As a technical consultant to the Obama Administration from 2009 to 2010, he helped develop the Patient Protection and Affordable Care Act.

Dr. Gruber discusses his healthcare reform experiences and shares his predictions for the future of healthcare with American Healthcare Journal staff writer, Caroline Miller.

Read More

August 31, 2020
Nursing Home Dialysis In The Time Of COVID-19

The coronavirus pandemic will spur major changes in the dialysis world, particularly when providing services to patients residing in the epicenters of the pandemic: nursing homes. More than one-third of all U.S. COVID-19 deaths are nursing home residents. There are nearly half a million hemodialysis patients in the United States, and more than 10 percent of these patients spend time at a nursing home at some point during a calendar year. This reflects both the vulnerability of the elderly population to COVID-19 infection and the difficulty in containing infection in these sequestered communities with residents living closely together.

Read More

FDA pulls emergency use authorization of hydroxychloroquine for COVID-19

Featured Articles

Let’s Use the State of SNF Therapy Today as a Springboard for More Positive Outcomes

Q&A: ACA Architect Predicts The Future Of Healthcare

Nursing Home Dialysis In The Time Of COVID-19

Featured Articles

Q&A: ACA Architect Predicts The Future Of Healthcare

Nursing Home Dialysis In The Time Of COVID-19

Combating The Ransomware Threat

McKinsey: ‘The Window To Act Is Now’ On Telehealth

FDA pulls emergency use authorization of hydroxychloroquine for COVID-19

Related Posts